Abstract: A staining kit is provided, including a first pattern including antibodies against T cell, B cell, NK cell, monocyte, regulatory cell, CD8, CD45, and CTLA4; a second pattern including antibodies against T cell, B cell, NK cell, monocyte, regulatory cell, dendritic cell, and CD45; a third pattern including antibodies against T cell, B cell, NK cell, monocyte, CD8, CD45, CD45RA, CD62L, CD197, CX3CR1 and TCR??; and a fourth pattern including antibodies against B cell, CD23, CD38, CD40, CD45 and IgM, wherein the antibodies of each pattern are labeled with fluorescent dyes. A method of identifying characterized immune cell subsets of a disease and a method of predicting the likelihood of NPC in a subject in the need thereof using the staining kit are also provided.

Abstract: A method for controlling obesity by using Antrodia camphorata is disclosed. A composition of Antrodia camphorata prepared from dried fruiting bodies of Antrodia camphorata is used to reduce lipid accumulation in adipocytes for controlling obesity, and the method includes steps of: providing a composition of Antrodia camphorata prepared from dried fruiting bodies of Antrodia camphorata; and applying the composition to reduce lipid accumulation for improving symptoms of obesity.

Abstract: In this patent, we isolated a novel compound from fruiting body of Antrodia cinnamomea, namely, (22R)-5?-lanosta-8,24-dien-3?,15?,21-triol. This compound possesses preferential cytotoxicity against human leukemia, pancreatic cancer, esophageal cancer, hepatoma, and cervical cancer cells.

Abstract: In this patent, we isolated a novel compound from fruiting body of Antrodia cinnamomea, namely, (22R)-5?-lanosta-8,24-dien-3?,15?,21-triol. This compound possesses preferential cytotoxicity against human leukemia, pancreatic cancer, esophageal cancer, hepatoma, and cervical cancer cells.

Abstract: The present invention relates to a method for inhibiting tumor growth, in particular to the method using dehydrosulphurenic acid to inhibit the growth of leukemia cell or pancreatic cancer cell by a compound extracted and purified from Antrodia cinnamomea. Dehydrosulphurenic acid of the invention can be used as a pharmaceutical composition to inhibit the tumor growth of leukemia or pancreatic cancer.

Abstract: This invention relates to a method for determining fruiting body and mycelium of Antrodia cinnamomea and Antrodia salmonea. By using ten known components in Antrodia cinnamomea including five ergostanes (antcins C and K, zhankuic acids A, B and C), four lanostanes (sulphurenic acid, dehydrosulphurenic acid, eburicoic acid, dehydroeburicoic acid), and one monophenyl (4,7-dimethoxy-5-methyl-1,3-benzodioxole) as standards, differentiation of mycelia and basidiomes of Antrodia cinnamomea was carried out in the invention. The natural basidiomes collected from wood of Cinnamomum kanehirai at natural forests and the cultural basidiomes grown on potato dextrose agar medium contained all ten tested components. However, the natural mycelia collected from wood of C. kanehirai at a natural forest and the liquid/solid cultural mycelia grown on potato dextrose broth/potato dextrose agar media contained the four lanostanes and 4,7-dimethoxy-5-methyl-1,3-benzodioxole, but not the five ergostanes.

Abstract: The present invention relates to a method for inhibiting tumor growth, in particular to the method using dehydrosulphurenic acid to inhibit the growth of leukemia cell or pancreatic cancer cell by a compound extracted and purified from Antrodia cinnamomea. Dehydrosulphurenic acid of the invention can be used as a pharmaceutical composition to inhibit the tumor growth of leukemia or pancreatic cancer.

Abstract: This invention relates to inflammatory responses in isolated peripheral human neutrophils that studied in the presence or absence of specially processed Radix Stephaniae tetrandrae (SPRST). We conclude that SPRST exerts anti-inflammatory effects by interfering with reactive oxygen species (ROS) production and calcium (Ca2+) influx through G-protein modulation to prevent Mac-1 up-regulation and firm adhesion by neutrophils during activation.Thns, SPRST may be clinical beneficial in the prevention of cardiovascular disease, or other diseases related to over activation of neutrophil.